Science & Product

FexoTopic (OP2101) is a lotion under development for treatment of mild and moderate Atopic Dermatitis, also called Eczema. It is envisaged as a short and long term "Eczema Ease & Prevent" monotherapy for adults and children from the age of 6 months. A main objective is to attain a pleasant skin-feel when applied to the sensitive skin of an atopic child. With FexoTopic we have taken a multi-pronged approach aimed at fast itch relief, inflammation control, suppression of bacterial imbalance, moisture retention, upregulation of antimicrobial peptides, and skin barrier restoration. In this strategy, FexoTopic targets the main pathological pillars of eczema.

The Atopic Dermatitis market is currently highly genericized, and no distinct trends in corporate strategy exist. However, over the coming decade the introduction of new drugs will emerge as a key future strategy for this marketplace. Unmet needs include the lack of therapeutic options, better long-term disease control and management, more tolerable topical treatment options, and improved patient treatment compliance. Children that comprises 75% of the patient group is known to be more vulnerable to adverse drug reactions, such as skin discomforts when treatments are applied. FexoTopic represents a significant opportunity to capture a share of this $5 billion-dollar annual market with a lotion that is tolerable, effective and economically attractive to payors.

‍